Evotec SE
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Christian Wojczewski
- Full Time Employees
- 4,553
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- Essener Bogen 7 Hamburg HA Germany 22419
- IPO Date
- Oct 11, 1999
- Website
- evotec.com
- Similar Companies
- Business
- Evotec SE operates as a global biotechnology company specializing in drug discovery and development solutions for the pharmaceutical and biotechnology industries worldwide. Its main products and services include drug discovery platforms and preclinical development in therapeutic areas such as neuroscience, diabetes, pain and inflammation, oncology, infectious diseases, respiratory and fibrotic diseases, cardiometabolic diseases, rare diseases, and women and animal health. Key segments include Shared R&D, which focuses on drug discovery and preclinical development leveraging automation, next-generation platforms, and AI to accelerate customer projects, and Just – Evotec Biologics, which designs, develops, and manufactures biologics through advanced continuous manufacturing technologies. Evotec provides integrated molecular design, upstream and downstream development, analytical and formulation development, and First-In-Human to commercial GMP biologics manufacturing services. The company serves pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capital worldwide, with operational presence in Germany, the United States, France, the United Kingdom, Switzerland, and other international locations. Founded in 1993 and headquartered in Hamburg, Germany, Evotec transitioned from Evotec AG to Evotec SE in 2019. Recent major changes include a transformational strategic agreement with Sandoz, announced in 2025, under which Sandoz will acquire 100% of Evotec's Just – Evotec Biologics EU manufacturing site in Toulouse along with an indefinite license to Evotec's proprietary continuous manufacturing platform. This transaction, valued at over $650 million including upfront payments, license fees, development revenues, and future royalties on a portfolio of biosimilars, marks a pivot to an asset-lighter business model for Evotec focused on technology provision and scalable biologics manufacturing services. This deal significantly enhances Evotec’s revenue mix and capital efficiency. Additionally, Evotec unveiled a new strategic focus in 2025 to concentrate on its core strengths in drug discovery and science leadership, emphasizing technology platforms and AI-driven innovation. New partnerships include multi-year research collaborations with Pfizer centered on metabolic and infectious diseases and a technology development partnership with Novo Nordisk to support next-generation cell therapies. These strategic moves underpin Evotec’s goal of sustainable, profitable growth while simplifying its business model and streamlining its asset portfolio by approximately 30 percent. Evotec’s integrated R&D value chain, proprietary technology platforms, and partnerships position it as a pioneering service partner in drug discovery and biologics manufacturing, delivering speed, efficiency, and quality solutions to accelerate development timelines and improve therapeutic outcomes. The company remains focused on advancing cutting-edge science, expanding its global footprint, and scaling its offerings to meet the evolving needs of the pharmaceutical and biotechnology sectors.
Company News
Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board
Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board
Evotec (NASDAQ:EVO) Sees Unusually-High Trading Volume – Time to Buy?
Evotec Announces Chief Scientific Officer Transition
Evotec Announces Chief Scientific Officer Transition
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
Evotec: The Market Seems Split On The Company's Prospects, Buy
Just - Evotec Biologics Advances U.S. Department of War Antibodies Against Orthopoxvirus into Phase 1 Clinical Studies
Just - Evotec Biologics Advances U.S. Department of War Antibodies Against Orthopoxvirus into Phase 1 Clinical Studies
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis
Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors
Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors
Brokerages Set Evotec AG (NASDAQ:EVO) PT at $3.00
Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases
Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases
Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168
Evotec Selects Navan to Unify Global Travel, Payments, and Expense Management
Evotec SE (EVO) Q2 2026 Earnings Call Transcript
Evotec Q2 Earnings Call Highlights
Ad hoc: Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook